Therapeutic efficacy of omalizumab in children with moderate-to-severe allergic asthma combined with chronic sinusitis

BackgroundOmalizumab has been approved for treating moderate-to-severe asthma in children aged over 6 years. Its application to asthmatic children with other allergic diseases has been rarely explored. The present study aims to explore the therapeutic efficacy of omalizumab in children with moderate...

Full description

Bibliographic Details
Main Authors: Weikun Chong, Hailang Li, Juan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Allergy
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/falgy.2023.1236798/full